Mostrando 1,761 - 1,780 Resultados de 84,353 Para Buscar '"HR"', tiempo de consulta: 0.44s Limitar resultados
  1. 1761
    “…For patients without BM, osimertinib + bevacizumab, osimertinib, aumolertinib, SoC + PbCT, dacomitinib, SoC + ramucirumab, SoC + bevacizumab, and afatinib showed superior efficacy compared with SoC (HR = 0.43, 95% CI: 0.20–0.90; HR = 0.46, 95% CI: 0.31–0.68; HR = 0.51, 95% CI: 0.34–0.77; HR = 0.50, 95% CI: 0.38–0.66; HR = 0.62, 95% CI: 0.43–0.89; HR = 0.64, 95% CI: 0.44–0.94; HR = 0.61, 95% CI: 0.48–0.76; HR = 0.71, 95% CI: 0.50–1.00), PbCT (HR = 0.29, 95% CI: 0.11–0.74; HR = 0.31, 95% CI: 0.15–0.62; HR = 0.34, 95% CI: 0.17–0.69; HR = 0.34, 95% CI: 0.18–0.64; HR = 0.42, 95% CI: 0.21–0.82; HR = 0.43, 95% CI: 0.22–0.87; HR = 0.41, 95% CI: 0.22–0.74; HR = 0.48, 95% CI: 0.31–0.75), and PfCT (HR = 0.14, 95% CI: 0.06–0.32; HR = 0.15, 95% CI: 0.09–0.26; HR = 0.17, 95% CI: 0.09–0.29; HR = 0.16, 95% CI: 0.10–0.26; HR = 0.20, 95% CI: 0.12–0.35; HR = 0.21, 95% CI: 0.12–0.39; HR = 0.20, 95% CI: 0.12–0.31; HR = 0.23, 95% CI: 0.16–0.34) in terms of PFS. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  2. 1762
    “…We evaluated 804 breast cancers and we identified 410 HER2-low tumors (336 with positive hormonal receptor status (HR+) and 74 with negative HR status (HR−)). HER2-enriched tumors were more frequent in HER2-low/HR− and HER2-low/HR+ subtypes, compared to HER2-negative/HR− and HER2-negative/HR+ subtypes, respectively (13.7% versus 1.6% and 1.2% versus 0.5%, respectively). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  3. 1763
    “…Also, adenine administration at 8 hr after ethionine completely reversed the nucleolar lesion by 12 hr. …”
    Enlace del recurso
    Enlace del recurso
    Texto
  4. 1764
    “…Higher educational level decreased the HR of esophageal cancer (HR = 0.61, 95%CI 0.42–0.90 in women, HR = 0.71, 95%CI 0.60–0.84 in men) and gastric cancer (HR = 0.80, 95%CI 0.63–1.03 in women, HR = 0.73, 95%CI 0.64–0.83 in men). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  5. 1765
    “…BACKGROUND: The purpose of this study was to explore the extent of associations of cardiovascular autonomic neuropathy (CAN) with metabolic syndrome (MetS) and resting heart reate (HR), and to evaluate the predictive value of MetS combined with HR on CAN in a large sample derived from a Chinese population. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  6. 1766
    “…In multivariate analysis, male gender (HR =1.898, P=0.001), sessile architecture (HR =3.249, P<0.001), high grade (HR =5.007, P<0.001), ipsilateral hydronephrosis (HR =4.768, P<0.001), renal pelvis location (HR =2.620, P<0.001) and tumor without multifocality (HR =1.639, P=0.028) were predictive factors for muscle invasive disease of UTUCs. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  7. 1767
  8. 1768
    “…Experimental sessions consisted of 10 JSs from five spots 5 m from basket at three different HRs: rest (0HR) and after warm-up (50% [50HR] and 80% maximal HR [80HR]). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  9. 1769
    “…The rates of change in HR were as follows: average HR acceleration before peak HR, 2.53 ± 0.80 bpm/s; peak HR acceleration before peak HR, 4.16 ± 1.08 bpm/s; and average HR deceleration after peak HR, −0.98 ± 0.30 bpm/s. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  10. 1770
    “…Such a significant association of was maintained subgroup of sample size of patients (> 150: for OS, HR = 1.77, and for DFS, HR = 0.91; or < 150: for OS, HR = 1.93, and for DFS, HR = 4.39), ethnicity (Asian: for OS, HR = 1.65, and for DFS, HR = 1.08; or not Asian: HR = 3.55, and for DFS, HR = 2.87), the data from database (clinical: for OS, HR = 1.24, and for DFS, HR = 1.40; or database: for OS, HR = 2.29, and for DFS, HR = 3.09), paper published year (after 2014: for OS, HR = 1.90;and for DFS,HR = 1.87; or before 2014: for OS, HR = 1.40, and for DFS, HR = 1.22); cancer type (female specific cancer: for OS, HR = 1.41, and for DFS, HR = 0.64; or non-gender specific cancers: for OS, HR = 2.00, and for DFS, HR = 2.95). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  11. 1771
    “…Age (<17 years, hazard ratio [HR] 2.92, 95% CI 2.28‐3.74; 75‐84 years, HR 1.29, 95% CI 1.16‐1.45; and ≥85 years, HR 1.71, 95% CI 1.45‐2.02, relative to age 55‐64), male gender (HR 1.26, 95% CI 1.16‐1.37), Charlson comorbidity index (HR 1.21, 95% CI 1.19‐1.23), and socioeconomic factors (Medifund use, HR 1.40, 95% CI 1.23‐1.59; housing subsidy type, HR 2.12, 95% CI 1.77‐2.54) were associated with increased risk of FA. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  12. 1772
    “…RESULTS: Impaired glucose tolerance was associated with ACM; HR 1.19, 95% CI (1.15 to 1.24), CVDM; HR 1.21, 95% CI (1.10 to 1.32), CVD; HR 1.18, 95% CI (1.11 to 1.26), CHD; HR; 1.13, 95% CI (1.05 to 1.21) and stroke; HR 1.24, 95% CI (1.06 to 1.45). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  13. 1773
    “…Based on univariate analysis results of age(P<0.001), metastases(P=0.012), disease stage(P=0.016), and number of renewed treatments(P<0.001), as well as multivariate analysis which was used to investigate the simultaneous effect of influencing variables on patients’ survival showed that age(61−70:HR=1.40,>70:HR=2.08), marital status(HR=0.39), number of renewed treatments(1:HR=0.54, 2:HR=0.30, 3:HR=0.22), relapse(HR=1.51), type of gastrectomy (Subtotal: HR=1.12, Distal:HR=0.49, Partial:HR=0.94, Proximal:HR=0.52), liver metastases (HR=1.79), distance metastases(HR=1.84), and disease stage(II:HR=1.28, III:HR=2.12, IV:HR=1.90) variables had a significant effect on patients’ survival. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  14. 1774
    “…In men, a moderate effect of assessment method on HR(max) was found (p = 0.001, η(2) = 0.066) with measured HR(max) higher than Fox-HR(max) (+2.8; 1.0, 4.6), Tanaka-HR(max) higher than Fox-HR(max) (+1.2; 0.7, 1.7). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  15. 1775
    “…Patients were divided into three groups based on the results of immunohistochemistry: HR+ (positive staining >10%), HR- (positive staining <1%) and low HR+ (positive staining 1–10%). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  16. 1776
  17. 1777
    “…As compared with the non-PPI group, the adjusted hazard ratio (aHR) were higher for incident organ specific ADs such as Graves disease (aHR=3.28), Hashmoto thyroiditis (aHR=3.61), autoimmune hemolytic anemia (aHR=8.88), immune thrombocytopenic purpura (aHR=5.05) Henoch-Schonlein pupura (aHR=4.83) and Myasthenia gravis (aHR=8.73). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  18. 1778
    “…In fully adjusted models, tertile 3 versus tertile 1 of average QT corrected (using the Fridericia correction) was associated with cardiac arrest (hazard ratio [HR], 1.66), heart failure (HR, 1.62), ventricular dysrhythmias (HR, 1.56), all CVD (HR, 1.31), ischemic heart disease (HR, 1.28), total stroke (HR, 1.18), and all‐cause mortality (HR, 1.24). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  19. 1779
    “…RESULTS: Compared with non-DM patients, OS in DM patients was significant shorter in lung cancer (HR = 2.076, P = 0.001 in early stage; HR = 2.118, P < 0.001 in advanced stage), digestive tract cancer (HR = 1.768, P = 0.020 in early stage; HR = 2.454, P = 0.005 in advanced stage), leukemia (HR = 2.636, P < 0.001), breast cancer (HR = 2.495, P = 0.047 in early stage; HR = 2.929, P = 0.019 in advanced stage) and liver cancer (HR = 3.086, P < 0.001 in early stage; HR = 2.219, P = 0.049 in advanced stage). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  20. 1780
    “…BACKGROUND: To investigate the predictive value of heart rate (HR) and blood pressure (BP) on the prognosis of postural tachycardia syndrome (POTS) in children. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
Herramientas de búsqueda: RSS